ZINATEM

This brand name is authorized in Nigeria.

Active ingredients

The drug ZINATEM contains a combination of these active pharmaceutical ingredients (APIs):

1	Artemether UNII C7D6T3H22J - ARTEMETHER
	Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
	Read more about Artemether
2	Lumefantrine UNII F38R0JR742 - LUMEFANTRINE
	Read more about Lumefantrine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-7158	Tablet	ZINATEM 20/120 TABLET TAB 20 mg; 120 mg 1 X 24	19 RNW-PP-260889 ZINATEM 20/120 TABLET ARTEMETHER 20MG + LUMEFANTRINE 120MG ACTIVE INGREDIENTS: ARTEMETHER 20MG, LUMEFANTRINE 120MG EXCIPIENTS: M.C.C.P 32MG, Lactose 28MG, Starch (SP-maize starch powder) 31.93MG, Bronopol 0.07MG, Cross carmellose sodium 10MG, P.V.P.K -30 8MG, Isopropyl Alcohol, Magnesium Stearate 10MG, Cross Carmellose Sodium 20MG, Talcum powder 3MG, Colloidal anhydrous silica 7MG B4-7158 Drugs ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS Imported Products 1X24 Over The Counter (OTC) 4/28/2022 ELIONA PHARMACEUTICAL COMPANY LIMITED, No. 6 Akinfenwa street off Celestial Way , Ori-Oke, Ogudu, Lagos. 8145462544 elionapharma@gmail.com SWISS PHARMA PVT LTD, 3709, G.I.D.C., PHASE-IV, VATVA, AHMEDABAD-382445, GUJARAT, INDIA, India	28/03/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-7158